Single antigen vaccines targeting p53 [51], SP17 [40], NY-ESO-1 [52], survivin [11], and WT1 [22] have been described to generate tumor antigen-specific cytotoxic T-cell lymphocytes (CTLs) able to lyse autologous tumor cells. This evidence concerns the gene WT1 and neoplasm.